Phamaniaga since signing an MOU with BioNet back in February has now entered into a Research Collaboration Agreement to collaborate and develop 6-in-1 combinational vaccine (“Hexavalent vaccine”) using BioNet formulation.
The formulation is scheduled to be ready by end of 2023, which will allow the company to proceed with pre-clinical & clinical development, registration, and manufacturing, and is expected to be commercialised in 2026.
Hexavalent vaccine (containing acellular pertussis) is currently used in the Malaysia National Immunisation Program (NIP) and is fully imported. As part of the Company’s vaccine development and manufacturing plan, Pharmaniaga will aggressively develop the Hexavalent vaccine in order to reduce import dependency and cost to the Government.
The local market demand for the Hexavalent vaccine is estimated to be around RM200 million annually. Pharmaniaga looks forward to supplying the Hexavalent vaccine to the Ministry of Health, Malaysia, and exporting to other parties worldwide. The demand for the regional market is expected to be around RM500-600 million annually.
Pharmaniaga said by having the first formulation for human vaccine will strengthen the company’s biopharmaceutical business footprint in the region and globally.
